Brainsway Gets FDA Approval for Multi-Center Bipolar Trial

Brainsway Ltd. said it received approval from the U.S. Food and Drug Administration to begin a multi-center trial to test the efficacy of its Deep TMS device for the treatment of bipolar disorder, according to a filing today with the Tel Aviv Stock Exchange.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE